Shall we cycle TNFi in AxSpA?
CorEvitas registry 86 pts
70% TNFi monotherapy, 23% NSAIDs, 42% high & 24% v high DA
Cycling to 2nd line TNFi
At 6 months: very low achievement of ASDAS-LDA (15%), MCID in ASDAS (7%) & no MI.
https://t.co/S9vnz5PXuX
Abs#1499 #ACR22 @Rheumnow https://t.co/1IZIYcPCBz
Links:
The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control…
http://bit.ly/3Gbpm9O
13-11-2022
